![Stig Anders Lindberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stig Anders Lindberg
Directeur/Membre du Conseil chez
CAMURUS AB
Fortune : 407 225 $ au 31/05/2026
Profil
Stig Anders Jakob Lindberg is the founder of Cellectricon AB, which was founded in 2000.
He held the title of Chief Executive Officer & Director at Cellectricon AB. Currently, Dr. Lindberg is the Chief Executive Officer & Director at Lindberg Life-Science AB. He is also a Director at Affibody AB, Affibody Medical AB, Amic AB, Dipylon Medical AB, Bostadsrattsforeningen Astraea, Oncopeptides Incentive AB, and Oncopeptides, Inc. Additionally, he serves as an Independent Director at Camurus AB starting in 2021.
In the past, Dr. Lindberg has held positions as a Director at Heartscape Technologies, Inc., an Independent Director at Alligator Bioscience AB, and a Director at Newron Pharmaceuticals SpA. He was also a Director at SciBase Holding AB, Newron Sweden AB, Atlas Antibodies AB, Vårdapoteket i Norden AB, Scibase Intressenter AB, Fiomi Diagnostics AB, Eirus Medical AB, Atlas Therapeutics AB, Ginolis AB, SciBase AB, Kihlstroms Frimarkshandel AB, Bostadsrattsforeningen Johannes Mindre, Merrill Lynch & Co., Inc., and McKinsey & Co., Inc. Dr. Lindberg worked as an Analyst at Merrill Lynch & Co., Inc. and as a Consultant at McKinsey & Co., Inc. He also served as a Vice President at Investor Growth Capital AB from 2004 to 2011.
From 2011 to 2024, he held the position of Chief Scientific Officer at Oncopeptides AB. Dr. Lindberg has a graduate and doctorate degree from Karolinska Institutet and an undergraduate degree from the University of Stockholm.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ONCOPEPTIDES AB 0,54 % | 31/12/2024 | 2 077 362 ( 0,54 % ) | 407 225 $ | 31/05/2026 |
Postes actifs de Stig Anders Lindberg
| Sociétés | Poste | Début |
|---|---|---|
| CAMURUS AB | Directeur/Membre du Conseil | 01/01/2021 |
Oncopeptides Incentive AB | Corporate Officer/Principal | - |
Bostadsrattsforeningen Astraea | Directeur/Membre du Conseil | - |
Lindberg Life-Science AB | Directeur Général | - |
Affibody AB
 Affibody AB BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops radioligand therapies for cancer treatment | Directeur/Membre du Conseil | - |
Dipylon Medical AB
 Dipylon Medical AB Pharmaceuticals: MajorHealth Technology Engages in the research and development of pharmaceutical products and manufactures medical instruments | Directeur/Membre du Conseil | - |
Affibody Medical AB
 Affibody Medical AB Pharmaceuticals: MajorHealth Technology Provides biopharmaceuticals services | Directeur/Membre du Conseil | - |
Amic AB
 Amic AB Medical SpecialtiesHealth Technology Develops in vitro diagnostic technologies for use in point-of-care diagnostic tests | Directeur/Membre du Conseil | - |
Oncopeptides, Inc.
 Oncopeptides, Inc. Medical/Nursing ServicesHealth Services Develops therapies for hematological diseases | Directeur/Membre du Conseil | - |
Anciens postes connus de Stig Anders Lindberg
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░ ░░░░░░░ ░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░░ ░░░░░ ░░░░░ ░░░░ ░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Stig Anders Lindberg
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
51
Relations au 1er degré
31
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 31 |
|---|---|
Merrill Lynch & Co., Inc. /Old/
 Merrill Lynch & Co., Inc. /Old/ Investment Banks/BrokersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services | Finance |
Cellectricon AB
 Cellectricon AB Miscellaneous Commercial ServicesCommercial Services Provides cell-based screening services to accelerate drug discovery | Commercial Services |
Heartscape Technologies, Inc.
 Heartscape Technologies, Inc. Medical SpecialtiesHealth Technology Develops and markets cardiology devices | Health Technology |
Affibody AB
Affibody AB BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops radioligand therapies for cancer treatment | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Provides biopharmaceuticals services | Health Technology |
Investor Growth Capital AB
 Investor Growth Capital AB Investment ManagersFinance IGC is a long-term investor with a top-down investment approach. They describe their investment attitude as patient and flexible. They are active investment partners seeking management teams operating in markets displaying sustainable growth characteristics. IGC commits themselves to board representation working closely for strategic decisions, financial and human resource allocations, potential acquisitions analyses and sources of additional capital. Their investee firms gain access to IGC's worldwide network of industry experts, advisors, and local knowledge over several geographic markets. IGC Europe invests primarily in expansion-stage firms in the technology and life sciences sectors in Northern Europe. They have an investment horizon from three to seven years. They typically invest between USD $3 million and $30 million. They acquire minority interest. IGC Asia targets expansion-stage firms in IT, software, semiconductors and Internet/media within Asia. Their investments range from USD $8 to $15 million over an investment period of three to six years. IGC US concentrates on investments in unlisted firms in healthcare and either listed or unlisted firms in IT sectors in North America. Generally, they invest in healthcare firms that have approved or marketed products. IT investments will typically be beyond the concept stage. | Finance |
Karolinska Institutet
 Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alligator Bioscience AB
 Alligator Bioscience AB BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops antibodies for the treatment of cancers | Health Technology |
Newron Pharmaceuticals SpA
 Newron Pharmaceuticals SpA Pharmaceuticals: MajorHealth Technology Develops and sells novel therapies central & peripheral nervous system | Health Technology |
SciBase Holding AB
 SciBase Holding AB Medical SpecialtiesHealth Technology Develops point of care device for the detection of malignant melanoma | Health Technology |
Amic AB
Amic AB Medical SpecialtiesHealth Technology Develops in vitro diagnostic technologies for use in point-of-care diagnostic tests | Health Technology |
Newron Sweden AB
 Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders | Health Technology |
University of Stockholm
 University of Stockholm Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oncopeptides AB
 Oncopeptides AB Pharmaceuticals: MajorHealth Technology Develops chemotherapeutic pharmaceuticals of compounds for cancer treatment | Health Technology |
Camurus AB
 Camurus AB Pharmaceuticals: MajorHealth Technology Provides nanoscale drug delivery systems for development of high value therapeutics | Health Technology |
Atlas Antibodies AB
 Atlas Antibodies AB BiotechnologyHealth Technology Develops, produces and markets reagents for biomedical research | Health Technology |
Dipylon Medical AB
Dipylon Medical AB Pharmaceuticals: MajorHealth Technology Engages in the research and development of pharmaceutical products and manufactures medical instruments | Health Technology |
Vårdapoteket i Norden AB
 Vårdapoteket i Norden AB Drugstore ChainsRetail Trade Owns and operates pharmacies | Retail Trade |
Scibase Intressenter AB | |
Fiomi Diagnostics AB
 Fiomi Diagnostics AB Medical SpecialtiesHealth Technology Develops, manufactures and markets diagnostic test kits | Health Technology |
Eirus Medical AB
 Eirus Medical AB Miscellaneous Commercial ServicesCommercial Services Provides medical technology development services | Commercial Services |
Atlas Therapeutics AB
 Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops and manufactures antibodies drugs | Health Technology |
Ginolis AB
 Ginolis AB Miscellaneous ManufacturingProducer Manufacturing Develops components in polymer | Producer Manufacturing |
Scibase AB | |
Lindberg Life-Science AB | |
Bostadsrattsforeningen Astraea | |
Kihlstroms Frimarkshandel AB | |
Bostadsrattsforeningen Johannes Mindre | |
Oncopeptides Incentive AB | |
Oncopeptides, Inc.
Oncopeptides, Inc. Medical/Nursing ServicesHealth Services Develops therapies for hematological diseases | Health Services |
